These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27623354)

  • 21. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.
    Patard JJ; Fergelot P; Karakiewicz PI; Klatte T; Trinh QD; Rioux-Leclercq N; Said JW; Belldegrun AS; Pantuck AJ
    Int J Cancer; 2008 Jul; 123(2):395-400. PubMed ID: 18464292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
    Kroeger N; Klatte T; Chamie K; Rao PN; Birkhäuser FD; Sonn GA; Riss J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    Cancer; 2013 Apr; 119(8):1547-54. PubMed ID: 23335244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
    Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
    Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells.
    Doberstein K; Wieland A; Lee SB; Blaheta RA; Wedel S; Moch H; Schraml P; Pfeilschifter J; Kristiansen G; Gutwein P
    Carcinogenesis; 2011 Mar; 32(3):262-70. PubMed ID: 21097529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
    Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
    Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
    Song Y; Huang J; Shan L; Zhang HT
    Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.
    Kim BJ; Kim JH; Kim HS; Zang DY
    Oncotarget; 2017 Feb; 8(8):13979-13985. PubMed ID: 28103578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic Significance of
    Kim HS; Kim JH; Jang HJ; Han B; Zang DY
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
    Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
    Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
    PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SERPINH1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker.
    Qi Y; Zhang Y; Peng Z; Wang L; Wang K; Feng D; He J; Zheng J
    J Cell Mol Med; 2018 Feb; 22(2):1224-1235. PubMed ID: 29239102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.